From: Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
Study name | Study status | Drug | Drug class | Intervention | Primary outcome | n | Median follow up | Start and end date | Clinicaltrials.gov ID |
---|---|---|---|---|---|---|---|---|---|
EMPEROR-preserved [37] | Completed | Empagliflozin | SGLT2 inhibitor | Empagliflozin 10 mg once daily vs. placebo | Composite of CV death or HHF | 5988 | 2.2 | 03.2017–04.2021 | NCT03057951 |
FIGARO-DKD [36] | Completed | Finerenone | Mineralocorticoid receptor antagonist | Finerenone 10 mg or 20 mg once daily vs. placebo | Composite of death from CV causes, nonfatal MI, nonfatal stroke, or HHF | 8246 | 3.4 | 09.2015–02.2021 | NCT02545049 |
AMPLITUDE-O [35] | Terminated | Efpeglenatide | GLP-1 receptor agonist | Efpeglenatide 4 mg or 6 mg subcutaneous once a week vs. placebo | Composite of nonfatal MI, nonfatal stroke, or death from CV or undetermined causes | 4077 | 1.8 | 04.2018–12.2020 | NCT03496298 |